Incidence of second malignancies during treatment of chronic
myeloid leukemia with tyrosine kinase inhibitors in the Czech
Republic and Slovakia

J 2011

Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia

VOGLOVÁ, Jaroslava, Jan MUŽÍK, Edgar FABER, Daniela ŽÁČKOVÁ, H. KLAMOVA et. al.

Základní údaje

Originální název

Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia

Autoři

VOGLOVÁ, Jaroslava (203 Česká republika, garant, domácí), Jan MUŽÍK (203 Česká republika, domácí), Edgar FABER (703 Slovensko, domácí), Daniela ŽÁČKOVÁ (203 Česká republika, domácí), H. KLAMOVA (203 Česká republika), Kateřina STEINEROVÁ (203 Česká republika, domácí), Z. MICHALOVICOVA (703 Slovensko), Ludmila DEMITROVIČOVÁ (703 Slovensko, domácí), Eduard CMUNT (203 Česká republika, domácí), L. NOVAKOVA (203 Česká republika), E. TOTHOVA (703 Slovensko), P. BELOHLAVKOVA (203 Česká republika), Jiří MAYER (203 Česká republika, domácí) a Karel INDRÁK (203 Česká republika, domácí)

Vydání

Neoplasma, 2011, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.440

Kód RIV

RIV/00216224:14110/11:00052944

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2011_03_256

UT WoS

000290695800012

Klíčová slova anglicky

chronic myeloid leukemia; tyrosine kinase inhibitor; incidence; second malignancy

Příznaky

Mezinárodní význam

Změněno: 3. 2. 2012 08:41, Mgr. Michal Petr

Anotace

V originále

Tyrosine kinase inhibitors (TKI) have completely changed the prognosis of patients with Ph+ chronic myeloid leukemia (CML). The occurrence of a second malignancy (SM) in CML patients successfully treated with TKI may significantly affect their prognosis. In a retrospective study of 1,038 patients with CML treated at 10 centers in the Czech Republic and Slovakia between 2000 and 2009, SM was detected in 35 (3.37%) patients after TKI therapy was initiated. The median intervals from the diagnosis of CML and from the start of TKI therapy to the diagnosis of SM were 58 months (range 2 - 214) and 32 months (range 1 - 102), respectively. The observed age-standardized incidence of SM after the start of TKI therapy was 8.95 / 1,000 person-years. Comparison of the incidence of SM in CML patients with population data was performed only for patients from the Czech Republic. The age-standardized incidence rate of all malignant tumors except non-melanoma skin cancers was 6.76 (95% CI: 6.74; 6.78) / 1,000 person-years in 2000 2007 while the incidence rate of SM in 708 CML patients from the Czech Republic treated with TKI was 9.84 (95% CI: 6.20; 13.48) / 1,000 person-years, i.e. 1.5-fold higher, although the difference was statistically insignificant. The distribution of SM types in CML patients treated with TKI was similar to that in the age-standardized general Czech population. The median overall survival (OS) of patients treated with TKI who also developed SM (57 months) was shorter than the OS of patients treated with TKI but not suffering from SM (median OS not reached, log rank test p<0.001). Prospective long-term population-based studies in CML patients treated with TKI as first-line therapy are needed to determine the relationship of SM to TKI therapy.

Citovat

VOGLOVÁ, Jaroslava, Jan MUŽÍK, Edgar FABER, Daniela ŽÁČKOVÁ, H. KLAMOVA, Kateřina STEINEROVÁ, Z. MICHALOVICOVA, Ludmila DEMITROVIČOVÁ, Eduard CMUNT, L. NOVAKOVA, E. TOTHOVA, P. BELOHLAVKOVA, Jiří MAYER a Karel INDRÁK. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma. 2011, roč. 58, č. 3, s. 256-262. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2011_03_256.

@article{948760,
   author = {Voglová, Jaroslava and Mužík, Jan and Faber, Edgar and Žáčková, Daniela and Klamova, H. and Steinerová, Kateřina and Michalovicova, Z. and Demitrovičová, Ludmila and Cmunt, Eduard and Novakova, L. and Tothova, E. and Belohlavkova, P. and Mayer, Jiří and Indrák, Karel},
   article_number = {3},
   doi = {http://dx.doi.org/10.4149/neo_2011_03_256},
   keywords = {chronic myeloid leukemia; tyrosine kinase inhibitor; incidence; second malignancy},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia},
   volume = {58},
   year = {2011}
}

TY  - JOUR
ID  - 948760
AU  - Voglová, Jaroslava - Mužík, Jan - Faber, Edgar - Žáčková, Daniela - Klamova, H. - Steinerová, Kateřina - Michalovicova, Z. - Demitrovičová, Ludmila - Cmunt, Eduard - Novakova, L. - Tothova, E. - Belohlavkova, P. - Mayer, Jiří - Indrák, Karel
PY  - 2011
TI  - Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia
JF  - Neoplasma
VL  - 58
IS  - 3
SP  - 256-262
EP  - 256-262
SN  - 00282685
KW  - chronic myeloid leukemia
KW  - tyrosine kinase inhibitor
KW  - incidence
KW  - second malignancy
N2  - Tyrosine kinase inhibitors (TKI) have completely changed the prognosis of patients with Ph+ chronic myeloid leukemia (CML). The occurrence of a second malignancy (SM) in CML patients successfully treated with TKI may significantly affect their prognosis. In a retrospective study of 1,038 patients with CML treated at 10 centers in the Czech Republic and Slovakia between 2000 and 2009, SM was detected in 35 (3.37%) patients after TKI therapy was initiated. The median intervals from the diagnosis of CML and from the start of TKI therapy to the diagnosis of SM were 58 months (range 2 - 214) and 32 months (range 1 - 102), respectively. The observed age-standardized incidence of SM after the start of TKI therapy was 8.95 / 1,000 person-years. Comparison of the incidence of SM in CML patients with population data was performed only for patients from the Czech Republic. The age-standardized incidence rate of all malignant tumors except non-melanoma skin cancers was 6.76 (95% CI: 6.74; 6.78) / 1,000 person-years in 2000 2007 while the incidence rate of SM in 708 CML patients from the Czech Republic treated with TKI was 9.84 (95% CI: 6.20; 13.48) / 1,000 person-years, i.e. 1.5-fold higher, although the difference was statistically insignificant. The distribution of SM types in CML patients treated with TKI was similar to that in the age-standardized general Czech population. The median overall survival (OS) of patients treated with TKI who also developed SM (57 months) was shorter than the OS of patients treated with TKI but not suffering from SM (median OS not reached, log rank test p<0.001). Prospective long-term population-based studies in CML patients treated with TKI as first-line therapy are needed to determine the relationship of SM to TKI therapy.
ER  -

VOGLOVÁ, Jaroslava, Jan MUŽÍK, Edgar FABER, Daniela ŽÁČKOVÁ, H. KLAMOVA, Kateřina STEINEROVÁ, Z. MICHALOVICOVA, Ludmila DEMITROVIČOVÁ, Eduard CMUNT, L. NOVAKOVA, E. TOTHOVA, P. BELOHLAVKOVA, Jiří MAYER a Karel INDRÁK. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. \textit{Neoplasma}. 2011, roč.~58, č.~3, s.~256-262. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2011\_{}03\_{}256.

Podrobný výpis o publikaci